1. Medtech Insight

Lawsuits To Stop FDA From Overseeing LDTs Could Create Chaos, Panelist Says

 
• By Brian Bossetta

As the 6 May deadline to implement the FDA’s final rule on lab-developed tests approaches, attempts to stop the rule from taking effect are set to play out in court. A panel of experts discussed the potential impact of these legal efforts, should they be successful, at the Medtech Conference in Toronto.

Nathan Brown and Carly McWilliams speak during a session on LDT regulations at the Medtech Conference in Toronto, Ontario, on 16 October.
Nathan Brown and Carly McWilliams speak during a session on LDT regulations at the Medtech Conference in Toronto, Ontario, on 16 October. (Brian Bossetta/Citeline)

When Congress at the end of 2022 failed to pass the VALID Act that would have establishing perimeters for the US Food and Drug Administration to regulate laboratory developed tests, it set in motion a chain of events that could spell pandemonium.

Key Takeaways

Ongoing lawsuits could upend the LDT industry, potentially leading to renewed interest in Congressional action.

The outcome will depend on the exact language of legal rulings, as well as actions taken under a new administration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform - Clone

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

More from Compliance